Looking for a synthetic VHH library with unmatched diversity?
Want access to our vast libraries?
VHHantage™
LlamdA®
Ultra-high diversity CDRs based on original llama frameworks. Equivalent to the circulating immune repertoire of 1 million llamas and built using Colibra® technology for reduced CMC liabilities.
HuLlamdA®
CIS display – Isogenica’s proprietary cell-free display system – overcomes this issue, allowing display of ～1012 individual VHHs (around 1000x bigger than phage display), and is a great match for our ultra-high diversity libraries.
Synthetic libraries for faster discovery
Due to the in vivo phenomenon of somatic hypermutation, it is easier to generate VHHs with extremely high affinities (picomolar range) from animal immunisations. Typically, leads from Isogenica’s synthetic libraries have low nanomolar affinities, which are optimal for drug development.
Quicker, cheaper, fewer liabilities
Immunisation of a large animal such as a llama or alpaca takes a lot of target antigen, and a long time. A good immune library can only be made after several months of waiting, boosting, and titre checking, and can take up to 8 months. In contrast, synthetic libraries can be mined immediately.
Furthermore, llama-derived hits require humanisation and may contain high-risk CMC liabilities such as extra cysteine residues or glycoslation sites. Isogenica’s libraries are built using methods designed to reduce the frequency of these liabilities and reduce the downstream engineering work required to turn immune-derived VHHs into potential drugs.
State-of-the-Art Technology
Tailored Display Strategies for Your Discovery Goals
Run all 3 libraries in parallel – powered by CIS Display™ or Phage Display, depending on your programme’s complexity and timelines.
At Isogenica, we optimize your discovery strategy by aligning platform choice with your targets,isog selection conditions, and project needs – whether you require high-throughput exploration or efficient standard workflows.
CIS Display™
- A DNA-based, cell-free display system designed for complex and high-throughput discovery.
- Up to 10¹⁴ display efficiency
- Supports VHH, peptide, and Centyrin® scaffolds
- Broad condition range: pH 3.5–8.5, salinity <5M NaCl, temp 4–37°C
- Up to 48 parallel selections
- Ideal for AI/ML triage, complex targets, and early data depth
- Best for: Complex programmes needing broader condition space, higher throughput, or early-stage richness — enabling confident triage and candidate optimization.
Phage Display
- A robust and well-established platform suited to streamlined discovery.
- Up to 10¹⁰ display efficiency
- 6-10 parallel selections
- Supports soluble proteins, nanodiscs, and cell-based formats
- Effective for typical project complexity
- Best for: Standard workflows where complexity is moderate and screening can be more focused and efficient.
Exclusive IP on up to 5 selected leads
Explore the science behind our antibody discovery platforms
White Paper “Data-Driven Validation of Synthetic VHHs”
This white paper provides a data-driven validation of Isogenica’s synthetic VHH libraries, powered by Colibra® technology. Designed for biotech and pharmaceutical scientists, it demonstrates how these libraries enhance and accelerate drug discovery, particularly in oncology and immunotherapy. DownloadExtending half-lives of VHH antibodies
Because VHHs are small, they can be cleared quickly from the bloodstream. This can be a useful feature for some applications, but often a longer plasma half-life is desirable. DOWNLOADAdvantages of VHH in bi-specifics
To learn more about the application of VHHs in bi-specifics, we have condensed our expertise into a downloadable Application Note. DOWNLOADOptimizing CAR-T and T-cell antibody engagers: a role for VHH single domain antibodies
This whitepaper summarises the clinical and research landscape for CAR-T and T-cell engaging antibody therapies and show how single domain VHH antibodies can be applied to optimise the next generation of these important new therapeutic modalities. DOWNLOADIsogenica’s PD-L1 VHH as Functional Antagonists
PD-1 is an immune checkpoint protein expressed on the surface of multiple types of immune cells, including antigen-stimulated T-cells and tumour specific T-cells1. Interaction between PD-1 and its ligands (PD-L1 or PD-L2), is responsible for the regulation of T-cell activation, apoptosis, proliferation and cytokine production. DOWNLOADAnti-LRP5/6 VHH inhibits WNT pathway and prevents tumour growth
VHH are the variable domain of heavy chain only antibodies. They are small in size (~15 kD) and biophysically robust. With tunable half-lives, these antibodies are ideal for targeting inaccessible epitopes, achieving enhanced tissue penetration, multi-target binding and formatting for payload delivery… DOWNLOAD